Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses.
about
Signal regulatory protein alpha (SIRPalpha)/CD47 interaction and functionTherapeutic opportunities for targeting the ubiquitous cell surface receptor CD47CD47 regulates bone mass and tumor metastasis to boneRadioprotection in normal tissue and delayed tumor growth by blockade of CD47 signalingClinical lung xenotransplantation--what donor genetic modifications may be necessary?Activated CD47 regulates multiple vascular and stress responses: implications for acute kidney injury and its managementThrombospondins as key regulators of synaptogenesis in the central nervous systemCD47 knockout mice exhibit improved recovery from spinal cord injury.The CD47-binding peptide of thrombospondin-1 induces defenestration of liver sinusoidal endothelial cellsAmyloid-β inhibits No-cGMP signaling in a CD36- and CD47-dependent mannerCD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humansThrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration.Cardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3.Thrombospondin-2 therapy ameliorates experimental glomerulonephritis via inhibition of cell proliferation, inflammation, and TGF-beta activation.Thrombospondin-1 activation of signal-regulatory protein-α stimulates reactive oxygen species production and promotes renal ischemia reperfusion injury.Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase.Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertensionPredictive model of thrombospondin-1 and vascular endothelial growth factor in breast tumor tissueElevated postinjury thrombospondin 1-CD47 triggering aids differentiation of patients' defective inflammatory CD1a+dendritic cells.CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice.Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47.Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow.Disruption of thrombospondin-2 accelerates ischemic fracture healing.Up-regulation of thrombospondin-2 in Akt1-null mice contributes to compromised tissue repair due to abnormalities in fibroblast function.Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1.CD47-independent effects mediated by the TSP-derived 4N1K peptide.Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1.Matricellular proteins in cardiac adaptation and disease.CD47 Promotes Protective Innate and Adaptive Immunity in a Mouse Model of Disseminated Candidiasis.Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1.The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47.Loss-of-function thrombospondin-1 mutations in familial pulmonary hypertensionMolecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.CD47 blockade reduces ischemia/reperfusion injury and improves survival in a rat liver transplantation model.Original insights on thrombospondin-1-related antireceptor strategies in cancer.Trauma patients' elevated tumor necrosis related apoptosis inducing ligand (TRAIL) contributes to increased T cell apoptosis.Secreted Thrombospondin-1 Regulates Macrophage Interleukin-1β Production and Activation through CD47.CD47 signaling pathways controlling cellular differentiation and responses to stress.Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stressRegulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies
P2860
Q24598828-DDB1A3B9-8BDF-4D41-B47B-CEC1A793074AQ24627155-D626EE67-ECC8-4BD3-804D-0CB1E57EAD88Q24651925-213CF2C6-116E-499D-ABBD-9FDA1B041EA2Q24657627-76D0A0E9-3323-4AAC-8653-12B5B8DC36F3Q26823663-6A7FD376-D09F-4B87-A2EF-43AA75DC33E3Q26864499-4F50E804-53A5-41AE-A3F0-41DCAAADEE4DQ27024828-9EBD2EDC-41EC-44A7-BC69-25452721DCA3Q27863417-5AD09158-822E-49D8-B170-F10ED969DB2FQ28293417-46388E48-A1D7-4D63-BB21-715D94F84D69Q28476620-ECDCDF5D-E44A-437E-83A9-47BB051C104BQ28543785-18CE950C-8132-4862-9DCD-0B75B38561E6Q30503997-4739451A-3A6D-4044-9E4C-2B2100DDB3A1Q30618651-A274F18B-5C1F-422D-9F3A-A11C6C38E3D4Q33499619-685AD3F0-B880-4661-BDC6-19A77743BF80Q33660552-B832216F-2EA6-4CD3-99A8-1D1EC0DED104Q33772904-64331ED5-EC2A-4C68-83C6-CC8D00B575DDQ33806253-F66EC6D4-8496-4DA0-84E1-9689D93FE12BQ33897971-937B9002-E34A-431C-8EAA-8F3EBCA01DFFQ34341392-42A1B3B0-FECB-4946-A7A0-0FC190BBA229Q34369179-EF0A510F-D2B8-4E21-9C02-73EAB5310AEBQ34385843-823F3FE7-BC22-4638-99C6-2BE84FAF99ADQ34527600-610D27B0-2634-437C-B09F-DAB7D05B9D94Q34529091-48B65F2E-4AEC-43DA-B76E-11F0020F3473Q34801542-E079ADCE-7950-41B4-BE3E-E9E804D28E25Q34869450-7E722923-7196-4C31-AE98-7B567707E223Q35171992-9FBA28E0-78C9-49FB-8562-9D2385A845BDQ35379312-717979C4-9A72-4610-B434-624A8D56140BQ35542423-AF5F0173-CE3F-4476-9350-7A9E88278621Q35648733-41E81496-C387-4F2B-9EE1-EFE40833DA22Q35792731-1E440393-3F5F-40AD-8B22-743898E0546AQ35809576-D392CB0E-D9AF-456D-AC47-F75A5A375273Q35850320-AFE73469-154B-4192-867B-93A2423200A5Q35902676-F159873A-1F0E-423F-8520-F38CA8B74640Q36148211-75766646-29A8-41F4-971D-E171097CAFB4Q36221374-E5E4849C-2ACC-4A59-AD2C-1B78715298E1Q36251532-93416B5F-604F-464D-8D67-57E2E08BFF40Q36507239-B1868CD4-89A4-42CA-BEAB-8F7DDD9F27EEQ36771076-57AA070C-AD23-41D3-AE51-51FB27AE71A9Q37144638-BF40693D-92ED-4461-9794-CFE8B6558B46Q37385797-007752D5-6A73-4AA5-AD4D-FEDAEA7BB349
P2860
Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Differential interactions of t ...... and ischemic injury responses.
@en
Differential interactions of t ...... and ischemic injury responses.
@nl
type
label
Differential interactions of t ...... and ischemic injury responses.
@en
Differential interactions of t ...... and ischemic injury responses.
@nl
prefLabel
Differential interactions of t ...... and ischemic injury responses.
@en
Differential interactions of t ...... and ischemic injury responses.
@nl
P2093
P2860
P356
P1476
Differential interactions of t ...... and ischemic injury responses
@en
P2093
Deane F Mosher
Douglas S Annis
Jeff S Isenberg
Malgorzata Ptaszynska
Michael L Pendrak
William A Frazier
P2860
P304
P356
10.1074/JBC.M804860200
P407
P577
2008-11-11T00:00:00Z